Navigation Links
CV Therapeutics to Announce 2007 Fourth Quarter and Year End Financial Results on Tuesday, February 26, 2008
Date:1/30/2008

PALO ALTO, Calif., Jan. 30 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) today announced that it will release fourth quarter and year end financial results for 2007 after the market closes on Tuesday, February 26, 2008. Company management will webcast a conference call at 5:00 p.m. EST, 2:00 p.m. PST, on the company's website.

To access the live webcast, please log on to the Company's website at http://www.cvt.com and go to the Investor Information section. Alternatively, domestic callers may participate in the conference call by dialing (866) 524-6247, and international callers may participate in the conference call by dialing (706) 679-3061. Webcast and telephone replays of the conference call will be available approximately two hours after the completion of the call through Tuesday, March 4, 2008. Domestic callers can access the replay by dialing (800) 642-1687, and international callers can access the replay by dialing (706) 645-9291; the PIN access number is 32378484.

About CV Therapeutics

CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases.

CV Therapeutics' approved product, Ranexa(R) (ranolazine extended-release tablets), is indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and should be used in combination with amlodipine, beta-blockers or nitrates.

CV Therapeutics also has other clinical and preclinical drug development candidates and programs, i
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Cryo-Cell Announces Research Collaboration Agreement with Saneron CCEL Therapeutics, Inc.
2. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
3. Allos Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
4. Cell Therapeutics, Inc. (CTI) Shareholders Authorize Share Increase at Special Meeting of Shareholders
5. Velcura Therapeutics, Inc. Can Begin Clinical Trials Following Successful Investigational New Drug Application to U.S. FDA
6. Nile Therapeutics Appoints Gregory W. Schafer to Board of Directors
7. Arno Therapeutics Completes License Agreements for the Exclusive Rights to Novel, Targeted Cancer Compounds
8. ImaRx Therapeutics Receives Urokinase Lot Release Approval With Extended Expiration Dating
9. Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer
10. Alba Therapeutics Appoints Wendy Perrow as its Vice President, Marketing and Alliance Management
11. Synvista Therapeutics to Develop Topical Formulation of ALT-2074 for the Treatment of Psoriasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... May 01, 2015 Spirax Sarco, the ... extremely proud to announce that for the first time ... a winner of a Queen’s Award for Innovation – ... design and manufacture of a unique flowmeter. , The ... alternative to traditional steam flow measurement. The device ...
(Date:4/30/2015)... SAN DIEGO , April 30, 2015   ... drugs, announced today an update on its Ebola antiviral ... of Tamir,s leading candidates, TMR004, is currently being evaluated ... frontline of the battle against Ebola. During the first ... Voice And Leadership Meeting To Accelerate The Evaluation of ...
(Date:4/30/2015)... , April 30, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: ... chemicals, today announced that it has commenced an underwritten public ... to grant the underwriters a 30-day option to purchase ... of common stock offered in the public offering. The ... be no assurance as to whether or when the ...
(Date:4/30/2015)... , April 30, 2015 Oxford Finance ... debt to life sciences and healthcare services companies, today ... term loan agreement with Celula, Inc., a diagnostic testing ... diseases, enabling better patient care and improved outcomes.  Proceeds ... development and expand the commercialization of its products in ...
Breaking Biology Technology:Spirax Sarco Receives a Queen’s Award for Innovation 2Spirax Sarco Receives a Queen’s Award for Innovation 3Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 2Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 3Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 4BioAmber Inc. Announces Public Offering Of Common Stock 2BioAmber Inc. Announces Public Offering Of Common Stock 3Oxford Finance Provides $10 Million Debt Financing to Celula 2
... Cardiac Science Corporation, an Opto Circuits Group ... defibrillator (AED) and diagnostic cardiac monitoring devices, announced ... G3 Pro® units to the Hong Kong Department ... http://photos.prnewswire.com/prnh/20080306/AQTH510LOGO ) "This alliance demonstrates ...
... LA JOLLA, Calif., Nov. 15, 2011 DermTech, ... disease detection, announced  it will present results from ... can be used with a high-throughput, low-cost qRT-PCR ... recapitulated on a qRT-PCR system that successfully discriminated ...
... Virobay, Inc., a privately held ... protease inhibitors for the treatment of autoimmune diseases, ... showing that one of the company,s spectrum-selective cathepsin ... bone cancer pain.  Virobay has a series of ...
Cached Biology Technology:Hong Kong Department of Health to Combat Sudden Cardiac Arrest With Powerheart AEDs 2Hong Kong Department of Health to Combat Sudden Cardiac Arrest With Powerheart AEDs 3Hong Kong Department of Health to Combat Sudden Cardiac Arrest With Powerheart AEDs 4DermTech's Non-invasive Melanoma Detection Assay Poised to Enter Clinical Validation Study 2DermTech's Non-invasive Melanoma Detection Assay Poised to Enter Clinical Validation Study 3Virobay's Spectrum-Selective Cathepsin Inhibitor Shows Efficacy in Bone Cancer Model 2Virobay's Spectrum-Selective Cathepsin Inhibitor Shows Efficacy in Bone Cancer Model 3
(Date:3/24/2015)... Mar. 24, 2015 Research and Markets ... "Global Iris Recognition Market 2015-2019" report to ... Iris Recognition market to grow at a CAGR of ... report covers the present scenario and the growth prospects ... 2015-2019. To calculate the market size, the report considers ...
(Date:3/23/2015)... March 23, 2015   HOYOS Labs , a ... today announced that the Company will demonstrate multiple biometrics-based ... and consumers at Connect:ID on March 23 through 25, ... Labs will highlight the IEEE Biometric Open Protocol Standard; ... and enterprise access control system. BOPS was invented by ...
(Date:3/20/2015)... March 20, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces ... one of the products featured in 2015 "I Want ... 11:00 PM EST on the DIY Network.   ... Las Vegas , site of the 2015 International ...
Breaking Biology News(10 mins):Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3
... are the first to observe the dynamic, ratchet-like movements ... proteins from genetic blueprints. Their study, published ... in the interplay of molecules that allows cells to ... use a variety of tools to build proteins, beginning ...
... of applying the strange properties of quantum mechanics to ... by a series of recent developments. The exciting progress ... and discussed recently at a high level conference organised ... Fonds zur Frderung der wissenschaftlichen Forschung in sterreich (FWF) ...
... NY, June 5, 2008 Allan C. Spradling, Ph.D., ... Medical Institute (HHMI) in Baltimore, is the recipient of ... Gruber Foundation for his work on fruit fly genomics ... reproduction." , For his contribution to developmental genetics, Spradling, ...
Cached Biology News:Researchers observe spontaneous 'ratcheting' of single ribosome molecules 2Researchers observe spontaneous 'ratcheting' of single ribosome molecules 3Europe gets together to harness quantum physics 2Europe gets together to harness quantum physics 3Europe gets together to harness quantum physics 4Spradling receives Gruber Foundation Genetics Prize for new genetic techniques 2Spradling receives Gruber Foundation Genetics Prize for new genetic techniques 3Spradling receives Gruber Foundation Genetics Prize for new genetic techniques 4
mu Opioid Receptor splice variant Immunogen: Synthetic peptide corresponding to residues K S C M D R G M R N L L P D D G P R Q E of Mu Opioid Receptor. Storage: -20 C, Avoid Freeze/Thaw Cycle...
Anti-Salmonid Ig (H), Alk Phos, (Clone IPA5F12) (mouse IgG2a)...
Rat monoclonal [HK5.3] to B7 RP1 (Phycoerythrin) ( Abpromise for all tested applications). entrezGeneID: 23308 SwissProtID: O75144...
... with the HECT protein, E6-AP ... Evidence suggests that this E2 ... degradation of non-""N-end rule"" protein ... -acetylated proteins as well as ...
Biology Products: